Literature DB >> 7586401

Early changes in regional and global left ventricular function after aortic valve replacement. Comparison of crystalloid, cold blood, and warm blood cardioplegias.

X Y Jin1, D G Gibson, J R Pepper.   

Abstract

BACKGROUND: The clinical effects of different cardioplegic methods on left ventricular (LV) function have not been fully elucidated, particularly in the setting of myocardial hypertrophy. METHODS AND
RESULTS: Sixty-four patients (mean age, 62 +/- 12 years; 41 men, 23 women) who were undergoing elective aortic valve replacement (stenosis, 49; regurgitation, 15; concomitant coronary artery bypass grafting, 22), with LV mass index 230 +/- 70 g/m2, were randomized to the following groups: antegrade crystalloid cardioplegia (CCP, 21 patients), antegrade/retrograde cold blood cardioplegia (CBP, 23 patients), or continuous retrograde warm (37 degrees C) blood cardioplegia (WBP, 20 patients). Mean aortic cross-clamp and cardiopulmonary bypass times were 100 +/- 20 and 126 +/- 24 minutes. Positive inotropic drug therapy was required postoperatively in 9 patients after CBP, 14 after CCP, and 18 after WBP. Perioperative LV function was assessed using transesophageal M-mode echocardiography, combined with high-fidelity LV pressure recording and thermodilution cardiac output, before bypass and 0.5, 1, 3, 6, 12, and 20 hours after cross-clamp removal. There was a similar fall in LV peak circumferential wall stress at constant LV end-diastolic dimension in each group after aortic valve replacement. The increase in contraction velocity was significant from 0.5 hour with CBP; however, no significant increase occurred until 12 hours with CCP and until 20 hours with WBP. The rate and extent of LV pressure fall and early diastolic filling rate both increased with CBP, and only in this group did ventricular coordination improve. LV stroke work index was maintained with CBP throughout the postoperative period with less inotropic support than with the other two methods.
CONCLUSIONS: In the hypertrophied LV, CBP offers the best preservation of myocardial physiological response and ventricular function with less inotropic support.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586401     DOI: 10.1161/01.cir.92.9.155

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Effects of incoordination on left ventricular force-velocity relation in aortic stenosis.

Authors:  X Y Jin; J R Pepper; D G Gibson
Journal:  Heart       Date:  1996-12       Impact factor: 5.994

2.  Comparison of the different cardioplegic strategies in cardiac valves surgery: who wins the "arm-wrestling"?

Authors:  Giuseppe Comentale; Raffaele Giordano; Gaetano Palma
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

3.  Expression and activity of the glutamate transporter EAAT2 in cardiac hypertrophy: implications for ischaemia reperfusion injury.

Authors:  Nicola King; Hua Lin; John D McGivan; M Saadeh Suleiman
Journal:  Pflugers Arch       Date:  2006-05-23       Impact factor: 3.657

4.  Aspartate transporter expression and activity in hypertrophic rat heart and ischaemia-reperfusion injury.

Authors:  Nicola King; Hua Lin; John D McGivan; M-Saadeh Suleiman
Journal:  J Physiol       Date:  2004-02-06       Impact factor: 5.182

5.  Retrograde hot-shot cardioplegia in patients with left ventricular hypertrophy undergoing aortic valve replacement.

Authors:  Raimondo Ascione; Saadeh M Suleiman; Gianni D Angelini
Journal:  Ann Thorac Surg       Date:  2008-02       Impact factor: 4.330

Review 6.  Cardioplegic strategies to protect the hypertrophic heart during cardiac surgery.

Authors:  M-S Suleiman; M Hancock; R Shukla; C Rajakaruna; G D Angelini
Journal:  Perfusion       Date:  2011-09       Impact factor: 1.972

7.  Operative Myocardial Protection in Patients with Left Ventricular Hypertrophy: The Role of Systemic Hypothermia.

Authors:  Tamer Elghobary; Idris M Ali; Ahmad F Ahmad
Journal:  Open J Cardiovasc Surg       Date:  2011-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.